However, the NPV of a radiological complete response (rCR) on DCE-MRI for identifying a pCR breast after NST in HER2-positive patients remains suboptimal and differs between hormone-receptor (HR)-positive (42–78%) and HR-negative breast cancer (69–88%) [15–20]. The gene discussed is ERBB2; the disease is breast carcinoma.